WO2024246838 - COMPOUNDS FOR THE DEGRADATION OF EGFR KINASE
National phase entry is expected:
Publication Number
WO/2024/246838
Publication Date
05.12.2024
International Application No.
PCT/IB2024/055315
International Filing Date
30.05.2024
Title **
[English]
COMPOUNDS FOR THE DEGRADATION OF EGFR KINASE
[French]
COMPOSÉS POUR LA DÉGRADATION DE LA KINASE EGFR
Applicants **
BEONE MEDICINES I GMBH
BEONE PHARMACEUTICAL (SUZHOU) CO., LTD.
Inventors
LEI, Bailin
ZHAO, Yizhou
QI, Xinzhu
LIU, Guanjun
WANG, Zhiwei
LIU, Huaqing
Priority Data
PCT/CN2023/097387
31.05.2023
CN
PCT/CN2023/125498
19.10.2023
CN
PCT/CN2024/090756
30.04.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 6081 | |
| EPO | Filing, Examination, Granting | 74337 | |
| Japan | Filing, Examination, Granting | 4218 | |
| South Korea | Filing, Examination, Granting | 6348 | |
| USA | Filing, Examination, Granting | 21340 |
Total:
112,324
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Disclosed herein are novel bifunctional compounds formed by conjugating EGFR inhibitor moieties with E3 ligase ligand moieties, methods of preparation, and uses thereof.[French]
L'invention concerne de nouveaux composés bifonctionnels formés par conjugaison de fractions d'inhibiteur d'EGFR avec des fractions de ligand de ligase E3, des procédés de préparation et des utilisations de ceux-ci.